Scarica l'app Stockscreener
1.05
5.41%
-0.06
Precedente Chiudi:
$1.11
Aprire:
$1.14
Volume 24 ore:
346.00K
Relative Volume:
0.41
Capitalizzazione di mercato:
$33.66M
Reddito:
-
Utile/perdita netta:
$-42.37M
Rapporto P/E:
-0.9826
EPS:
-1.0686
Flusso di cassa netto:
$-34.94M
1 W Prestazione:
+40.06%
1M Prestazione:
-13.22%
6M Prestazione:
-75.86%
1 anno Prestazione:
-66.13%
Intervallo 1D:
$1.03
$1.14
Intervallo di 1 settimana:
$0.731
$1.15
Portata 52W:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Confronta SKYE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
3.64 | 4.50B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.50 | 447.72M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.61 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.30 | 322.97M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.49 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Is Skye Bioscience Inc. (09R) stock a safe buy pre earnings2025 Winners & Losers & AI Powered Trade Plan Recommendations - ulpravda.ru
Is Skye Bioscience Inc. stock a safe haven assetQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - ulpravda.ru
Why hedge funds are buying Skye Bioscience Inc. stock2025 Investor Takeaways & AI Forecast Swing Trade Picks - ulpravda.ru
What margin trends mean for Skye Bioscience Inc. stockTrade Exit Summary & Fast Gain Stock Trading Tips - ulpravda.ru
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pend - GuruFocus
Is Skye Bioscience Inc. (09R) stock worth holding before Fed meetingPortfolio Gains Summary & Daily Stock Trend Watchlist - ulpravda.ru
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your RightsSKYE - PR Newswire
Lawsuit Alert: Investors who lost money with shares of Skye - openPR.com
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Burned by Skye Bioscience, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back - ACCESS Newswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - Your Wyoming Link
Levi & Korsinsky Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SKYE - GlobeNewswire
ROSEN, A TOP-RANKED LAW FIRM, Encourages Skye Bioscience, - GlobeNewswire
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
SKYE LAWSUIT ALERT: Levi & Korsinsky Notifies Skye Bioscience, Inc. InvestorsLead Plaintiff Deadline January 16, 2026 - ACCESS Newswire
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm - PR Newswire
Lost Money on Skye Bioscience, Inc. (SKYE)? Contact Levi & Korsinsky Before January 16, 2026 to Join Class Action - ACCESS Newswire
HALO, Skye Bioscience team up on obesity drug development - Longevity.Technology
Skye Bioscience, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your RightsSKYE - Finviz
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Prime Publishers, Inc.
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors - GlobeNewswire
Fibonacci Retracement Aligns with Support in Rudra Ecovation LimitedEx-Dividend Date Alerts & Free Long-Term Investment Planning - earlytimes.in
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Investors in Skye Bioscience, Inc. (SKYE): Protect Your RightsContact Levi & Korsinsky Before January 16, 2026 - ACCESS Newswire
Shareholders of Skye Bioscience, Inc. (SKYE): Protect Your Rights Before January 16, 2026Contact Levi & Korsinsky - ACCESS Newswire
Shareholders SueWallSt in New Class Action Against Skye Bioscience, Inc.Act Now - Stockhouse
Citizens reiterates Market Outperform rating on Skye Bioscience stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman LLC Urges Skye Bioscience, - GlobeNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc - GuruFocus
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - MarketScreener
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc.(SKYE) of a Class Action Lawsuit and an Upcoming Deadline - Barchart.com
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Skye Bioscience rises as it partners with Halozyme on obesity drug - TradingView — Track All Markets
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
SKYE ALERT: Securities Fraud Class Action Launched Against Skye Bioscience, Inc.January 16, 2026 Deadline - ACCESS Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Skye Bioscience, Inc. (SKYE) Investors of January 16, 2026 Deadline - ACCESS Newswire
Levi & Korsinsky Urges Skye Bioscience, Inc. (SKYE) Shareholders to Act Before Lead Plaintiff Deadline January 16, 2026 - ACCESS Newswire
Class Action Lawsuit Filed: Skye Bioscience, Inc. (SKYE) – Join by January 16, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
Will Breakout in Rathi Bars Limited Sustain Through Next WeekPortfolio Allocation Tips & Double Or Triple Returns - earlytimes.in
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Your Wyoming Link
William Blair Initiates Coverage of Skye Bioscience (SKYE) with Outperform Recommendation - MSN
Securities Fraud Class Action Filed Against Skye Bioscience, Inc. (SKYE)Levi & Korsinsky Reminds Investors of January 16, 2026 - ACCESS Newswire
Lost Money on Skye Bioscience, Inc.(SKYE)? Join Class Action Sui - GuruFocus
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - FinancialContent
Investor Alert: Deadline Approaching to Join Skye Bioscience, Inc. (SKYE) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):